AstraZeneca and Daiichi Sankyo have the confirmatory ... the number of cases of interstitial lung disease – a rare but serious side effect linked to Enhertu – was also in line with earlier ...

Already making inroads as a treatment for HER2-positive breast cancer, AstraZeneca and Daiichi ... cell lung cancer (NSCLC) have gone a long way towards building positive sentiment to Enhertu ...

The US Food and Drug Administration (FDA) has approved Daiichi Sankyo and AstraZeneca’s Enhertu for adults with ... positive (IHC 3+) non-small cell lung cancer patients and reported a confirmed ...

On the heels of receiving a landmark FDA approval in breast cancer, AstraZeneca and Daiichi Sankyo drug Enhertu won an additional approval in non-small cell lung cancer. The decision makes the ...

Narrow-moat Daiichi Sankyo is ... early commercial success of Enhertu and good clinical data of Dato-DXd in previously treated lung cancer. Additionally, Daiichi Sankyo and its Enhertu commercial ...

Narrow-moat Daiichi Sankyo’s second-quarter earnings were ... driven by favorable foreign exchange and sales expansion of Enhertu and Lixiana. Still, they were partially tempered by decreased ...

AstraZeneca and Daiichi Sankyo have announced that their therapy Enhertu has shown a statistically and clinically meaningful progression-free survival (PFS) improvement in patients with HR ...

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...

Recommended Reading AstraZeneca and Daiichi’s next cancer medicine scores in breast tumors An experimental medicine from AstraZeneca and Daiichi Sankyo failed to help people with a common form ...

Daiichi Sankyo ... ENHERTU has been conditionally approved by China's National Medical Products Administration (NMPA) as a single agent for adult patients with a specific type of non-small cell ...

(Alliance News) - AstraZeneca PLC on Monday said that its antibody drug conjugate Enhertu won another approval ... by AstraZeneca and Tokyo-based Daiichi Sankyo Co Ltd. "Since our initial approval ...